MGO One Seven LLC Raises Position in Becton, Dickinson and Company (NYSE:BDX)

MGO One Seven LLC lifted its stake in Becton, Dickinson and Company (NYSE:BDX) by 2.3% in the 2nd quarter, HoldingsChannel reports. The firm owned 4,165 shares of the medical instruments supplier’s stock after acquiring an additional 93 shares during the period. MGO One Seven LLC’s holdings in Becton, Dickinson and Company were worth $973,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. Livelsberger Financial Advisory purchased a new stake in Becton, Dickinson and Company in the fourth quarter worth about $27,000. OLD Point Trust & Financial Services N A bought a new position in shares of Becton, Dickinson and Company during the 4th quarter valued at approximately $29,000. Scarborough Advisors LLC purchased a new stake in Becton, Dickinson and Company in the 4th quarter worth approximately $32,000. Rise Advisors LLC bought a new stake in Becton, Dickinson and Company during the 1st quarter worth approximately $38,000. Finally, ICA Group Wealth Management LLC purchased a new position in Becton, Dickinson and Company during the fourth quarter valued at approximately $42,000. 86.97% of the stock is owned by institutional investors.

Becton, Dickinson and Company Stock Down 0.7 %

Shares of BDX opened at $233.94 on Friday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.85 and a quick ratio of 1.36. The stock has a market capitalization of $67.62 billion, a price-to-earnings ratio of 51.53, a price-to-earnings-growth ratio of 1.91 and a beta of 0.42. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $269.52. The business’s 50 day simple moving average is $234.71 and its 200-day simple moving average is $235.67.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.31 by $0.19. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The company had revenue of $4.99 billion for the quarter, compared to the consensus estimate of $5.08 billion. During the same quarter in the prior year, the firm earned $2.96 earnings per share. Becton, Dickinson and Company’s revenue was up 2.3% on a year-over-year basis. As a group, equities analysts expect that Becton, Dickinson and Company will post 13.1 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, September 30th. Investors of record on Monday, September 9th will be given a $0.95 dividend. The ex-dividend date of this dividend is Monday, September 9th. This represents a $3.80 annualized dividend and a yield of 1.62%. Becton, Dickinson and Company’s dividend payout ratio is currently 83.70%.

Wall Street Analyst Weigh In

Several brokerages have recently commented on BDX. Citigroup decreased their price objective on shares of Becton, Dickinson and Company from $260.00 to $255.00 and set a “neutral” rating on the stock in a research report on Wednesday, July 10th. Raymond James lowered their price objective on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research report on Friday, August 2nd. The Goldman Sachs Group began coverage on Becton, Dickinson and Company in a research report on Thursday, May 30th. They set a “buy” rating and a $274.00 target price for the company. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Finally, Stifel Nicolaus increased their price objective on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a report on Friday, July 26th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $279.50.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.